Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis....

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

nuBioAge, a longevity science and wellness network based in West Palm Beach, has announced a partnership between their new comprehensive assessment and research center, nuHx, and Marius Pharmaceuticals, the company behind KYZATREX® (testosterone...

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by...

Merz Aesthetics launches Ultherapy PRIME, the next generation of nonsurgical skin lifting treatments

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime....

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Restore Hyper Wellness and MECOTEC are proud to announce an exciting new partnership that brings together two industry leaders in the field of cryotherapy and wellness services. As part of this collaboration, MECOTEC has acquired Restore's...

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

The capsules and tablets commonly used today consist of loose or lightly compressed particles of the drug and excipients. After ingestion, they disintegrate almost immediately in the stomach. The small drug particles then flow from the stomach and...

ChromaDex expands its pharmaceutical-grade Niagen® IV and injection offerings to more leading wellness clinics.

ChromaDex Corp. the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics that will offer pharmaceutical-grade Niagen®...

Zydus announces an exclusive licensing and supply agreement for two Gadolinium-based MRI injectable contrast agents in the U.S

Zydus Lifesciences Ltd., a global innovation driven pharma company that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit), an innovation...

City of Hope and BRC treat first patient with BRC-001 in a breast cancer care trial.

City of Hope®, one of the largest cancer research and treatment organizations in the United States, and Biopharmaceutical Research Company (BRC), a specialty pharmaceutical company developing proprietary cannabinoid therapeutics, announced that...

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Sergio Santillana, MD, MSc, MBA, as Chief Medical...

BeiGene highlights TEVIMBRA® data in lung and gastrointestinal cancers

BeiGene, Ltd. a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab).“TEVIMBRA has shown potential across multiple disease states, and the data at further supports its position as the foundational asset of...

Stealth BioTherapeutics announces an FDA advisory committee meeting to review Elamipretide for Barth syndrome treatment

Stealth BioTherapeutics Inc. a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced that the U.S. Food and Drug...

Lunit joins Roche's Digital Pathology Open Environment to advance cancer biomarker testing

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced its collaboration with Roche to integrate Lunit SCOPE PD-L1 22C3 TPS into Roche's navify® Digital Pathology platform. This marks...

AISA Pharma receives FDA orphan drug designation for AISA-021, a treatment for systemic sclerosis

Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021(cilnidipine), a fourth-generation calcium channel antagonist. Aisa is...

Genprex collaborators to present positive preclinical data on Reqorsa® gene therapy

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR...

The Muscular Dystrophy Association and Forge Biologics announce AAV development

Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced it will be the adeno-associated virus (AAV) development and manufacturing partner for the Muscular Dystrophy Association’s...

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that the company’s Life Science business achieved EXCiPACT cGMP (current Good Manufacturing Practice) certification for Pharmaceutical Auxiliary...

Onco360 now offers LAZCLUZE™ (lazertinib) with Rybrevant® for first-line treatment of metastatic non-small cell lung cancer with specific EGFR mutations

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE™ (lazertinib). LAZCLUZE™. Is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase...

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Cygnus Technologies both part of Maravai LifeSciences (NASDAQ: MRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an...

ProJenX announces the formation of its Clinical Advisory Board

ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, announced the...